natgillin/translations-raw huggingface dataset:
A method according to claim 1 or claim 2 wherein the plant is a crop plant selected from field crops fruits, vegetables, nuts, peanuts, berries, tropical plantations, ornamentals and others, such as wheat, barley, rye, oats, rice, maize, sorghum, beans, lentils, peas, soybeans, rape, mustard, poppy, sugar- and fodder- beet, cotton, flax, hemp, jute, sunflowers, castor oil, groundnuts, potatoes, tobacco, sugar cane, apples, pears, plums, peaches, nectarines, apricots, cherries, oranges, lemons, grapefruit, mandarins, olives vines, hops, almonds, walnuts, hazelnuts, avocado, bananas, tea, coffee, coconut, cocoa, natural rubber plants, oil plants, strawberries, raspberries, blackberries, spinach, lettuce, asparagus, cabbages, Chinese kale, carrots, onions, tomatoes, cucumbers, pepper, eggplants, melons, paprika, chilli, roses, chrysanthemums and carnations. 
Postupak prema zahtjevu 1 ili zahtjevu 2 naznačen time da biljka je usjev odabran od ratarskih kultura voća, povrća, orašastih plodova, kikirikija, bobičastog voća, tropskih nasada, ukrasnog bilja i drugog, kao što su pšenica, ječam, raž, zob, riža, kukuruz, sirak, grah, leća, grašak, soja, repica, gorušica, mak, šećerna i krmna repica, pamuk, lan, konoplja, juta, suncokret, ricinusovo ulje, kikiriki, krumpir, duhan, šećerna trska, jabuke, kruške, šljive, breskve, nektarine, marelice, trešnje, naranče, limuni, grejp, mandarine, maslina, vinova loza, hmelj, bademi, orasi, lješnjaci, avokado, banane, čaj, kava, kokos, kakao, biljke prirodne gume, uljarice, jagode, maline, kupine, špinat, salata, šparoge, kupus, kineski kelj, mrkva, luk, rajčica, krastavci, paprika, patlidžan, dinja, paprika, čili, ruže, krizanteme i karanfili.
A method according to claim 3 wherein the plant is tomato, tobacco, peanut or barley. 
Postupak prema zahtjevu 3 naznačen time da biljka je rajčica, duhan, kikiriki ili ječam.
A method according to claim 1 or claim 2 wherein the plant is susceptible to damage by viral infections transmitted by whitefly, aphid, leafhopper or thrips. 
Postupak prema zahtjevu 1 ili zahtjevu 2 naznačen time da je biljka osjetljiva na oštećenja od virusnih infekcija koje prenose štitasti moljac, uši, cvrčci ili trips.
The pharmaceutical composition in form of emulsion or microemulsion according to claim 1, wherein said composition is an oil-in-water emulsion or microemulsion. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 1, gdje je taj pripravak emulzija ili mikroemulzija ulje-u-vodi.
The pharmaceutical composition in form of emulsion or microemulsion according to claim 3, wherein said viscosity is measured at about 25°C, at about 30°C and/or at about 37°C. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 3, gdje se ta viskoznost mjeri na oko 25°C, oko 30°C i/ili oko 37°C.
The pharmaceutical composition in form of emulsion or microemulsion according to claim 10, wherein said at least one lipophilic compound is selected from natural oils, such as almond oil, canola oil, castor oil, corn oil, cottonseed oil, olive oil, safflower oil, sesame oil, soybean oil; fatty acid esters, such as isopropyl palmitate, isopropyl myristate, ethyl oleate; fatty alcohols, such as myristic alcohol, oleyl alcohol; fatty acids, such as myristic acid, oleyl acid, palmitic acid, triglycerides, such as long and/or medium-chain triglycerides; diglycerides and monoglycerides. 
Farmaceutski pripravak u obliku emulzije ili mikroemulzije prema zahtjevu 10, gdje se taj barem jedan lipofilni spoj odabire između prirodnih ulja, kao što su bademovo ulje, kanola ulje, ricinusovo ulje, kukuruzno ulje, pamučno ulje, maslinovo ulje, ulje šafranike, sezamovo ulje, sojino ulje; estera masnih kiselina, kao što su izopropil palmitat, izopropil miristat, etil oleat; masnih alkohola, kao što su miristinski alkohol, oleinski alkohol; masnih kiselina, kao što su miristinska kiselina, oleinska kiselina, palmitinska kiselina; triglicerida, kao što su dugolančani i/ili srednjelančani trigliceridi; diglicerida i monoglicerida.
A compound of claim 1 or claim 2 for use in a method of inhibiting the binding of an IAP protein to a caspase protein, wherein said method comprises contacting said IAP protein with said compound of claim 1 or claim 2. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u postupku inhibiranja vezanja proteina IAP na protein kaspazu, gdje se navedeni postupak sastoji u stavljanju u kontakt navedenog proteina IAP s navedenim spojem u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2.
A compound of claim 1 or claim 2 for use in a method of inhibiting the binding of an IAP protein to a caspase protein according to claim 7, characterized in that said method is an in vitro method. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u postupku inhibiranja vezanja proteina IAP na protein kaspazu u skladu s patentnim zahtjevom 7, naznačen time što je navedeni postupak postupak in vitro.
A compound of claim 1 or claim 2 for use in a method for treating a disease or condition associated with the overexpression of an IAP in a mammal. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u postupku liječenja bolesti ili stanja povezanog s prekomjernom ekspresijom IAP kod sisavca.
A compound of claim 1 or claim 2 for use in a method of sensitizing a cell to an apoptotic signal according to claim 12, characterized in that said method is an in vitro method. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, namijenjen upotrebi u postupku sensibiliziranja stanice na apoptotski signal u skladu s patentnim zahtjevom 12, naznačen time što je navedeni postupak postupak in vitro.
A compound of claim 1 or claim 2 for the use according to the claims 12 and 13, wherein said apoptotic signal is induced by contacting said cell with a compound selected from the group consisting of cytarabine, fludarabine, 5-fluoro-2'-deoxyuiridine, gemcitabine, methotrexate, bleomycin, cisplatin, cyclophosphamide, adriamycin (doxorubicin), mitoxantrone, camptothecin, topotecan, colcemid, colchicine, paclitaxel, vinblastine, vincristine, tamoxifen, finasteride, docetaxel and mitomycin C. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevima 12 i 13, gdje se navedeni apoptotski signal izaziva stavljanjem navedene stanice u kontakt sa spojem kojeg se bira iz skupine koju čine citarabin, fludarabin, 5-fluor-2′-deoksiuiridin, gemcitabin, metotreksat, bleomicin, cisplatin, ciklofosfamid, adriamicin (doksorubicin), mitoksantron, kamptotecin, topotekan, kolcemid, kolhicin, paklitaksel, vinblastin, vinkristin, tamoksifen, finasterid, docetaksel i mitomicin C.
A compound of claim 1 or claim 2 for the use according to the claims 12 and 13, wherein said apoptotic signal is induced by contacting said cell with Apo2L/TRAIL. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevima 12 i 13, gdje se navedeni apoptotski signal izaziva stavljanjem navedene stanice u kontakt s Apo2L/TRAIL.
A compound of claim 1 or claim 2 for use in a method for treating cancer. 
Spoj u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što je namijenjen upotrebi u postupku liječenja raka.
A pharmaceutical composition comprising the compound of claim 2 and at least one pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 2, kao i najmanje jednu farmaceutski prihvatljivu podlogu, razrjeđivač ili pomoćnu tvar.
dissolving erythromycin or an erythromycin salt or a mixture thereof in acetone or a mixed solvent comprising acetone under alkaline condition to form a solution of the erythromycin or erythromycin salt; 
otapanje eritromicina ili soli eritromicina ili njihove smjese u acetonu ili smjesi otapala koja sadrži aceton pod alkalnim uvjetima da nastane otopina eritromicina ili sol eritromicina;
The method of claim 3, wherein sodium hydroxide, potassium hydroxide, ammonium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate or a combination thereof is used to adjust the pH in step a. 
Postupak prema zahtjevu 3, naznačen time da se za podešavanje pH u koraku a) koriste natrijev hidroksid, kalijev hidroksid, amonijev hidroksid, natrijev karbonat, kalijev karbonat, natrijev bikarbonat, kalijev bikarbonat ili njihova kombinacija.
The method of any one of claims 1-5, wherein the content of the acetone in the mixed solvent is more than 40%, or more than 50%, or more than 60%, or more than 70%, or more than 80%, or more than 90% by volume; wherein the other solvent is an alcohol solvent, an ether solvent, a halogenated solvent, an ester solvent, a ketone solvent other than acetone, water or a combination thereof; wherein the alcohol solvent is a C1-C6 alcohol; the ether solvent is tetrahydrofuran, diethyl ether, dioxane, methyl tert -butyl ether, dimethoxyethane, diethylene glycol dimethyl ether, triethylene glycol dimethyl ether or a combination thereof; the halogenated solvent is dichloromethane, 1,2-dichloroethane, chloroform or a combination thereof; the ester solvent is ethyl acetate, isopropyl acetate, butyl acetate or a combination thereof; and the ketone solvent is butanone. 
Postupak prema bilo kojem od zahtjeva 1-5, naznačen time da je udio acetona u smjesi otapala veći od 40%, ili veći od 50%, ili veći od 60%, ili veći od 70%, ili veći od 80%, ili veći od 90% po volumenu; pri čemu drugo otapalo je alkoholno otapalo, etersko otapalo, halogenirano otapalo, estersko otapalo, ketonsko otapalo osim acetona, voda ili njihova kombinacija; pri čemu alkoholno otapalo je C1-C6 alkohol; etersko otapalo je tetrahidrofuran, dietil eter, dioksan, metil tert-butil eter, dimetoksietan, dietilen glikol dimetil eter, trietilen glikol dimetil eter ili njihova kombinacija; halogenirano otapalo je diklormetan, 1,2-dikloretan, kloroform ili njihova kombinacija; estersko otapalo je etil acetat, izopropil acetat, butil acetate ili njihova kombinacija; i ketonsko otapalo je butanon.
The method of any one of claims 1-7, wherein the pH of the solution in step c is adjusted to-from 6.0 to 7.5, or from 7.0 to 7.5 by a weak acid, and wherein the weak acid is an inorganic acid, an organic acid or a combination thereof, or the weak acid is dilute acetic acid, dilute hydrochloric acid, dilute sulfuric acid, dilute phosphoric acid, dilute nitric acid or a combination thereof. 
Postupak prema bilo kojem od zahtjeva 1-7, naznačen time da se pH otopine u koraku c) podešava na od 6.0 do 7.5, ili od 7.0 do 7.5 sa slabom kiselinom, te pri čemu slaba kiselina je anorganska kiselina, organska kiselina ili njihova kombinacija, ili slaba kiselina je razrijeđena octena kiselina, razrijeđena solna kiselina, razrijeđena sumporna kiselina, razrijeđena fosforna kiselina, razrijeđena dušična kiselina ili njihova kombinacija.
The method of any one of claims 1-9, wherein the solution is filtered to remove insoluble solid impurities before adding the thiocyanate salt. 
Postupak prema bilo kojem od zahtjeva 1-9, naznačen time da se otopina prije dodavanja tiocijanatne soli filtrira radi uklanjanja netopljivih krutih nečistoća.
Use according to claim 2 wherein the compound of formula (I) is in solid crystalline form having a X-ray powder diffraction pattern containing one, two, three or four peaks selected from (± 0.2) 17.6, 18.4, 22.5 and 24.2 degrees 2-theta. 
Spoj prema zahtjevu 1, naznačen time da spoj s formulom (I) u krutom kristalnom obliku ima uzorak difrakcije X-zraka na prahu koji obuhvaća vrhove kod (± 0.2) 17.6, 18.4, 22.5 i 24.2 stupnjeva 2-theta.
A compound for use according to claim 9 wherein the endoparasitic infection is caused by a helminth selected from the group consisting of Anaplocephala, Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocyclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Triodontophorous, Uncinaria, Wuchereria, and combinations thereof. 
Ariloazol-2-il-cijanoetilamin za uporabu prema zahtjevu 11, naznačen time, da je endoparazitna infekcija uzrokovana helmintom odabranim iz skupine koju čine: Anaplocephala (Anoplocephala), Ancylostoma, Anecator, Ascaris, Brugia, Bunostomum, Capillaria, Chabertia, Cooperia, Cyathostomum, Cylicocylclus, Cylicodontophorus, Cylicostephanus, Craterostomum, Dictyocaulus, Dipetalonema, Dipylidium, Dirofilaria, Dracunculus, Echinococcus, Enterobius, Fasciola, Filaroides, Habronema, Haemonchus, Metastrongylus, Moniezia, Necator, Nematodirus, Nippostrongylus, Oesophagostumum, Onchocerca, Ostertagia, Oxyuris, Paracaris, Schistosoma, Strongylus, Taenia, Toxocara, Strongyloides, Toxascaris, Trichinella, Trichuris, Trichostrongylus, Tridontophorus, Uncinaria, Wuchereria, i njihove kombinacije.
The pharmaceutical composition according to claim 3 or 5 in the form of a liquid composition or a solid composition designed to be reconsituted e.g. 
Farmaceutski sastav prema zahtjevu 3 ili 5 u obliku tekućeg sastava ili krutog sastava dizajniranog da se rekonstituira npr.
A pharmaceutical composition comprising alpha-1-microglobulin. 
Farmaceutski sastav koji sadrži alfa-1-mikroglobulin za uporabu kao lijek.
A pharmaceutical tablet for oral administration comprising: 
Farmaceutska tableta za oralnu primjenu koja sadrži:
from 3 wt% to 18wt% of ulipristal acetate, wherein ulipristal acetate is present in the tablet in an amount ranging from 1 mg to 50 mg together with the following excipients: 
od 3 tež% do 18tež% ulipristal acetata, gdje je ulipristal acetat prisutan u tableti u količini u rasponu od 1 mg do 50 mg zajedno sa sljedećim pomoćnim tvarima:
from 60 wt% to 95 wt% of a diluent selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, and hydrates thereof, cellulose, and microcrystalline cellulose, 
od 60 tež% do 95 tež% punila odabranog iz skupine koju čine monosaharidi, disaharidi, šećerni alkoholi, te njihovi hidrati, celuloza i mikrokristalična celuloza.
from 0.5 wt% to 4 wt% of magnesium stearate wt% designating an amount by weight, as a percentage of the total weight of the composition. 
od 0.5 tež% do 4 tež% magnezijevog stearata tež% označava količinu po težini, kao postotak ukupne težine pripravka.
The tablet of claim 1, wherein the binding agent is in an amount of 1 to 10 wt%. 
Tableta prema zahtjevu 1, gdje je vezivo u količini od 1 do 10 tež%.
A method of manufacturing a ulipristal acetate tablet according to any of claims 1 to 14, the method comprising mixing the ingredients and ulipristal acetate and forming a tablet, preferably by wet granulation or by direct compression. 
Postupak proizvodnje tablete ulipristal acetata prema bilo kojem od zahtjeva 1 do 14, postupak obuhvaća miješanje sastojaka i ulipristal acetata te oblikovanje tablete, poželjno vlažnom granulacijom ili direktnim komprimiranjem.
An engineered gram-negative bacterium host strain comprising a drugless plasmid wherein said drugless plasmid comprises a polynucleotide encoding a cI repressor protein and having at least 90% sequence identity to a polynucleotide having the sequence as set forth in SEQ ID NO:1, 45, 47, 49, 51, 53, 55, 57, or 59 and wherein the bacterium host comprises one or more-copies of a heterologous polynucleotide in a nonessential region of the bacterial chromosome, wherein the heterologous polynucleotide encodes a product that is toxic to the host, wherein the heterologous polynucleotide comprises a sacB gene which encodes a SacB protein having at least 90% sequence identity to a polypeptide having the sequence as set forth in SEQ ID NO:4, 60, 62, 64, 66, 68,70, 72, or 74 and wherein the heterologous polynucleotide is operably linked to a promoter from λ phage having the sequence as set forth in SEQ ID NO:5. 
Promijenjeni soj gram-negativne bakterije domaćina, putem inženjeringa, naznačen time, da obuhvaća plazmid bez ljekovite tvari, pri čemu spomenuti plazmid bez lijeka obuhvaća polinukleotid koji kodira cl represivni protein i ima najmanje 90% identiteta sekvence od polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:1, 45, 47, 49, 51, 53, 55, 57 ili 59, te pritom bakterija domaćin sadrži jednu ili više kopija heterolognog polinukleotida u netemeljnom području bakterijskog kromosoma, dok heterologni polinukleotid kodira proizvod koji nije toksičan za domaćina, gdje heterologni polinukleotid sadrži sacB gen koji kodira SacB protein koji ima najmanje 90% identiteta sekvence od polipeptida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:4, 60, 62, 64, 66, 68, 70, 72 ili 74, te time, da je heterologni polinukleotid funkcionalno povezan na promotor iz λ-faga koji sadrži sekvencu prikazanu u SEQ ID NO:5.
The bacterium strain according to claim 1 wherein the bacterium host comprises two or more copies of the heterologous polynucleotide in a nonessential region of the bacterial chromosome. 
Bakterijski soj prema zahtjevu 1, naznačen time, da bakterija domaćin sadrži dvije ili više kopija heterolognog polinukleotida u netemeljnom području od bakterijskog kromosoma.
The bacterium host strain according to claim 1 or 2 wherein the bacterium strain is selected from the group consisting of Avibacterium, Brucella, Escherichia coli, Haemophilus (e.g., Haemophilus suis), Salmonella (e.g., Salmonella enteritis, Salmonella typhimurium, Salmonslla infantis), Shigella, Pasteurella, and Rimeirella . 
Soj bakterije domaćina prema zahtjevu 1 ili 2, naznačen time, da je bakterijski soj odabran iz skupine koju čine Avibacterium, Brucella, Escherichia coli, Haeomophilus (primjerice Haemophilus suis), Salmonella (primjerice Salmonella enteritis, Salmonella typhimurium, Salmonella infantis), Shigella, Pasteurella, i Rimeirella.
The bacterium host strain of any one of claims 1 to 5, wherein the bacterium strain comprises one or more copies of a polynucleotide having the sequence as set forth in SEQ ID NO:75. 
Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 5, naznačen time, da bakterijski soj sadrži jednu ili više kopija polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:75.
Antibody 005-C04 or defined maturated variants thereof according to table 5 or antigen-binding fragments thereof which antagonize prolactin receptor (PRLR)-mediated signaling and which bind to epitopes of the extracellular domain of the prolactin receptor and human polymorphic variants thereof whereby the amino acid sequence of the extracellular domain of the prolactin receptor corresponds to SEQ ID NO: 70, and the nucleic acid sequence corresponds to SEQ ID NO: 71, whereby SEQ ID NO: 6 of the variable heavy chain of the antibody 005-C04 corresponds to HCDR1, Seq ID NO: 12 corresponds to HCDR2 and Seq ID NO: 17 corresponds to HCDR3, and Seq ID NO: 23 of the variable light chain corresponds to LCDR1, Seq ID NO: 28 corresponds to LCDR2 and Seq ID NO: 33 corresponds to LCDR3,, and whereby 
Antitijelo 005-C04 ili njihove definirane sazrjele varijante u skladu s tablicom 5 ili njegov fragment koji veže antigene koji antagonizira signalizaciju posredovanu s prolaktinskim receptorom (PRLR) i koje se veže na epitope izvanstanične domene receptora prolaktina i njihove ljudske polimorfne varijante naznačeno time da sekvenca amino kiseline izvanstanične domene prolaktin receptora odgovara SEQ ID NO: 70, te sekvenca nukleinske kiseline odgovara SEQ ID NO: 71, pri čemu SEQ ID NO: 6 promjenjivog teškog lanca antitijela 005-C04 odgovara HCDR1, Seq ID NO: 12 odgovara HCDR2 i Seq ID NO: 17 odgovara HCDR3, i Seq ID NO: 23 promjenjivog lakog lanca odgovara LCDR1, Seq ID NO: 28 odgovara LCDR2 i Seq ID NO: 33 odgovara LCDR3, te pri čemu
Antibody and antigen-binding fragment according to claim 1 and 2, whereby the antibody consists of an antigen-binding region that binds specifically to or has a high affinity of for one or more regions of PRLR, whose amino acid sequence is depicted by SEQ ID NO: 70 and human polymorphic variants of SEQ ID NO: 70, amino acid position 1 to 210, whereby the affinity is at least 30 nM, more preferred with an affinity of less than about 10 nM, or even more preferred with an affinity of less than 1 nM. 
Antitijelo i fragment koji veže antigen prema zahtjevu 1 i 2, naznačeno time da se antitijelo sastoji od područja koje veže antigen koje se specifično veže na ili ima visoki afinitet za jednu ili više regija od PRLR, navedena sekvenca amino kiseline je prikazana sa SEQ ID NO: 70 i ljudskim polimorfnim varijantama iz SEQ ID NO: 70, položajem amino kiseline 1 do 210, pri čemu je afinitet barem 30 nM, poželjnije s afinitetom od manje od oko 10 nM, ili čak još poželjnije s afinitetom od manje od 1 nM.
Host cell comprising the vector of claim 6 or a nucleic acid molecule of 5, whereby the host cell is a higher eukaryotic host cell, a lower eukaryotic host cell, or a prokaryotic cell. 
Stanica domaćin, naznačena time da sadrži vektor prema zahtjevu 6 ili molekulu nukleinske kiseline prema zahtjevu 5, pri čemu stanica domaćin je viša eukariotska stanica domaćin, niža eukariotska stanica domaćin, ili prokariotska stanica.
Antibody or antigen-binding fragment according to any of claims 1 to 4 for use as a medicament for treatment and/or prevention of endometriosis and adenomyosis (endometriosis interna). 
Antitijelo ili fragment koji veže antigen prema bilo kojem od zahtjeva 1 do 4 naznačeno time da je za uporabu kao lijek za liječenje i/ili prevenciju endometrioze i adenomioze (endometriosis interna).
A treatment agent for use in the treatment of the relapsing-remitting or secondary progressive multiple sclerosis at the time of relapse, comprising N-[7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-1-benzopyran-3-yl]formamide or a salt thereof. 
Terapijsko sredstvo za uporabu u liječenju povratno-odložene ili sekundarno progresivne multipla skleroze, u vrijeme povraćaja, naznačeno time, da sadrži N-[7-[(metilsulfonil)amino]-4-okso-6-fenoksi-4H-1-benzopiran-3-il] formamid ili sol istog.
Use of a pharmaceutical tablet comprising: 
Farmaceutska tableta za oralnu primjenu koja sadrži:
The use of claim 1, wherein the tablet comprises from 1 to 10 wt% of binding agent. 
Tableta prema zahtjevu 1, gdje je vezivo u količini od 1 do 10 tež%.
The population of placental-derived adherent cells for use of claim 1 or 2, wherein said placental-derived adherent cells are additionally one or more of CD45-, or CD90+, as detectable by flow cytometry. 
Populacija adherentnih stanica dobivenih iz placente za uporabu prema zahtjevu 1, gdje su adherentne stanice dobivene iz placente dodatno jedna ili više od CD45-, ili CD90+, kako je određeno citometrijom.
The pharmaceutical dosage formulation of claim 1, wherein the formulation is a solid dosage form. 
Farmaceutska dozna formulacija iz patentnog zahtjeva 1, naznačena time što je formulacija čvrsti dozni oblik.
The pharmaceutical dosage formulation of claim 2, formulated as a tablet. 
Farmaceutska dozna formulacija iz patentnog zahtjeva 2, formulirana kao tableta.
The pharmaceutical dosage formulation of claim 3, comprising about 100mg of the compound having the structure: 
Farmaceutska dozna formulacija prema patentnom zahtjevu 3, koja sadrži oko 100 mg spoja koji ima strukturu:
The pharmaceutical dosage formulation of any one of claims 1-4, wherein the pharmaceutically acceptable carrier comprises a diluent, a binder, an adhesive, a disintegrant, a lubricant, an antiadherent, a glidant, or a combination thereof. 
Farmaceutska dozna formulacija prema bilo kojem od patentnih zahtjeva od 1 do 4, naznačena time što farmaceutski prihvatljiv nosač sadrži diluent, vezivo, adheziv, dezintegrator, lubrikant, antiadheziv, glidant, ili njihovu kombinaciju.